Work Procedures for the Priorty Review of Drugs for Marketing Authorization (Trial)

Home News Insights

Database

Laws & Regulations

Drug Catalog ChP Standards

Events

Webinars Offline Events

Services

Work Procedures for the Priorty Review of Drugs for Marketing Authorization (Trial)

Local Title:药品上市许可优先审评审批工作程序（试行）
Country/Region:Chinese Mainland
Competent Authority: National Medical Products Administration (NMPA)
Type:Regulation
Status:In force
Release Date:2020-07-08
Implementation Date:2020-07-08

Request

Document

Language	Source	Title	Access
ZH	Official	药品上市许可优先审评审批工作程序（试行）	Download

Summary

Priority Review (PR) is one of the four expedited programs for drug registration in China. The document introduces the qualification for applying for PR and the review process of the applications.